Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Pembrolizumab - anti-PD-1 antibody
Pembrolizumab- anti-PD-1 antibody · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Active | OTHER | Phase 1/2 open-label |
| Name | Type | Description |
|---|---|---|
| LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER | DRUG | LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER |
| Pembrolizumab - anti-PD-1 antibody | BIOLOGICAL | pembrolizumab- anti-PD-1 antibody |
Prescreening Inclusion Criteria for genotyping: 1. Has histopathologically confirmed locally advanced or metastatic solid tumor cancer. 2. Is able to understand and voluntarily sign a written informed consent form and is willing and able to comply with protocol requirements. 3. Is considered likely...
Pembrolizumab is an investigational anti-PD-1 monoclonal antibody being studied for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development, with an active trial evaluating its safety, tolerability, pharmacokinetics, and anti-tumor effects in this patient population.
Pembrolizumab targets the programmed cell death protein 1 (PD-1) receptor. As an anti-PD-1 antibody, it is designed to modulate the immune system's response to cancer cells, though the specific mechanism of action in solid tumors is being investigated in ongoing clinical trials.
Pembrolizumab is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in adult patients with solid tumors.
Pembrolizumab is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and pharmacokinetic profile in adults with solid tumors.
Pembrolizumab is being studied in one active Phase 1 clinical trial, NCT04130516, titled 'Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801 alone and With Pembrolizumab.' This trial is recruiting 200 adult participants with solid tumors in the United States.
Yes, Pembrolizumab is the same as Pembrolizumab- anti-PD-1 antibody. The name 'Pembrolizumab- anti-PD-1 antibody' is an alternative designation for the drug, which is also known simply as Pembrolizumab. Both names refer to the same investigational anti-PD-1 monoclonal antibody.